Beleave Inc. (BE: CNX) has entered into an interim streaming agreement with PanCann Streaming Corp. to finance the purchase and construction of a proposed second production facility to be identified, in exchange for equity participation in, and a production yield allocation from the proposed facility.
This agreement, if funded, would allow Beleave to substantially increase its potential production capacity on a non-dilutive basis to Beleave’s shareholders.
Key Terms of the Agreement:
The parties will work cooperatively to identify an appropriate second site to be acquired and developed by a newly formed special purpose subsidiary of Beleave (“NewCo”{A }).
The proposed second site is expected to be located in Ontario and will be designed to accommodate 200,000 square feet of cultivation space.
Once such a site and the construction budget for the new facility have been agreed on, PanCann will provide, among other things, (i) up to $5 million to fund the purchase of the second site and (ii) all necessary funding to complete the construction of the new facility. In return, PanCann will receive a 50% equity interest in NewCo and 50% of the proceeds (net of certain costs) of future wholesale or retail sales completed by NewCo.
“This opportunity allows Beleave to add supply beyond its current expansion plans, as well as explore wholesale opportunities that will not interfere with our potential patient sales in the future. This will increase our top line while eliminating the need for capital expenditure,” says Roger Ferreira, CEO and Director of Beleave. “A completely accretive agreement for Beleave Inc., and the start of a new and exciting partnership with PanCann.”
The agreement remains subject to a number of precedent conditions, including availability of financing on the part of PanCann, receipt by Beleave of applicable Health Canada and other regulatory approvals, due diligence by the parties, execution of definitive agreements, and the ability of the parties to agree on future construction budgets and timelines. There is no assurance that the PanCann financing will be completed on the terms contemplated herein or at all.
About Beleave
Beleave Inc. is a biotech company committed to becoming a licensed producer under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”). Beleave’s wholly-owned subsidiary First Access Medical Inc. (“FAM”) has applied for a license to cultivate and sell medical cannabis pursuant to the ACMPR. As of the date hereof, FAM has successfully advanced past the review stage, and completed its pre-licensing inspection. Beleave’s purpose-built facility is located near Hamilton, Ontario.
In the interest of full disclosure, we call the reader’s attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.
Read Next
